Market Research Report
Biopharmaceuticals Market (By TypeMonoclonal Antibodies, Recombinant Proteins, Granulocyte Colony-Stimulating Factor, Interferon, & Others; By Therapeutic Application; By Geography) Global Scenario, Market Size, Outlook, Trend and Forecast, 2015-2024
|Published by||Variant Market Research LLP||Product code||550293|
|Published||Content info||115 Pages
Delivery time: 2-3 business days
|Biopharmaceuticals Market (By TypeMonoclonal Antibodies, Recombinant Proteins, Granulocyte Colony-Stimulating Factor, Interferon, & Others; By Therapeutic Application; By Geography) Global Scenario, Market Size, Outlook, Trend and Forecast, 2015-2024|
|Published: August 28, 2017||Content info: 115 Pages||
(Monoclonal Antibodies, Recombinant Proteins, Granulocyte Colony-Stimulating Factor, Interferon, Recombinant Human Insulin, Erythropoietin, Vaccines, Growth Hormones, Purified Proteins; Oncology, Inflammatory Infectious Diseases, Metabolic Disorders, Cardiovascular Diseases; North America, Europe, Asia-Pacific, and RoW) Global Scenario, Market Size, Outlook, Trend and Forecast, 2015-2024.
Global Biopharmaceuticals Market is estimated to reach $405 billion by 2024; growing at a CAGR of 9.3% from 2016 to 2024. Biopharmaceuticals are proteins and nucleic acids that are produced by means of recombinant DNA techniques, purification processes, and hybridoma techniques. The production of these medical drugs mainly involves transgenic organisms, largely plants, and animals that have been genetically modified to produce drugs. Biopharmaceuticals are basically proteins in nature comprising of antibodies and nucleic acids and are used for vivo diagnostic purpose and therapeutic. They aid in the treatment of several chronic diseases including metabolic, cardiovascular, neurological, cancer and other intermittent diseases for which no other treatments are available at present.
Advanced technologies, improved efficiency as compared to conventional drugs, and increasing prevalence of autoimmune diseases and cancer are the major factors driving the growth of the global biopharmaceuticals market. Additionally, increasing government investments for the development of advanced products, and growing preference of herbal medicines could offer future scope in the coming years. Though, possibility of adverse effects and presence of low priced biosimilars could limit the adoption among end users.
The global biopharmaceuticals market has been categorized into type, therapeutic application, and geography. Type segment is bifurcated into purified proteins, interferon, monoclonal antibodies, granulocyte colony-stimulating factor (G-CSF), recombinant proteins, recombinant human insulin, erythropoietin, vaccines, growth hormones, and others. Therapeutic application is further segmented into oncology, metabolic disorders, inflammatory infectious diseases, cardiovascular diseases, and others.
By geography, the biopharmaceuticals market has been categorized into North America, Europe, Asia-Pacific, and Rest of the World (RoW). The U.S., Canada, and Mexico are covered under North America wherein Europe covers Germany, UK, France, Italy, and others. Asia-Pacific covers India, Japan, China, and others. Rest of the World (RoW) covers South America, Middle East, and Africa.
The key players in the global biopharmaceuticals market include Eli Lilly and Company, Biocon Ltd, Roche Holding AG, Bayer AG, Johnson & Johnson, Inc, Genentech, Inc., Abbott Laboratories, Ranbaxy Laboratories Ltd., Pfizer Inc., Novartis AG, GlaxoSmithKline plc, and Biogen, Inc, among others.